A Phase 3 interventional study of EU Avastin® and BAT1706 in Non-squamous Non-small Cell Lung Cancer, sponsored by Bio-Thera Solutions. Completed at 5 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-14.
Sponsored by Bio-Thera Solutions · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 763 open to participants now, 987 under way, 203 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.
Among the 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 129th largest by enrollment of the 1,594 interventional ones that give a count, is one of 83 that started in 2017, is one of 366 in phase 3, and was the 419th registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →763 of the 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:
Full-Life Technologies UK Limited · Sites in China, United States, Australia
Ages 18+
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Ruijin Hospital · Sites in China
Ages 18+
Daiichi Sankyo · Sites in China, United States, Argentina and 10 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,881 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 361 · Phase 2 849 · Phase 3 404 · Phase 4 40
First in 1996; this study’s year is marked. 83 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 651 is above the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 100 across the 1,594 interventional studies, 200 across the 287 observational. Of the 454 that completed or were terminated, 130 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
805 of 1,881 have an industry lead sponsor. The 10 most frequent:
Bio-Thera Solutions is the lead sponsor of 57 studies on the registry; 4 are open to participants now.
Bio-Thera Solutions has 3 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
224 of the studies in Carcinoma, Non-Small-Cell Lung with a site in China that are under way reach primary completion within a year, 33 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06448312Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2026-11 |
| NCT06704620Phase 3Tianjin Medical University Cancer Institute and HospitalStudy of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist(Diphenhydramine)in Advanced and Metastatic Non-Small Cell Lung Cancer | 2026-11 |
| NCT05429463Phase 3Second Affiliated Hospital, Zhejiang University, School of MedicineNeoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC(neoSCORE Ⅱ) | 2026-11-30 |
| NCT06711900Phase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | 2026-12 |
| NCT06382129Phase 3Sichuan Baili Pharmaceutical Co., Ltd.A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02) | 2026-12 |
Add all 224 to your calendar (.ics) → With an account.
Among the 1,881 studies in Carcinoma, Non-Small-Cell Lung with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase III, randomized, double blind, multicenter, active comparator, parallel two arm study to compare the efficacy, and to evaluate the safety, and immunogenicity of BAT1706 to EU Avastin® in patients with previously untreated advanced non-squamous non-small cell lung cancer (nsNSCLC) to demonstrate clinical equivalence of BAT1706 and EU Avastin®.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug:EU Avastin® 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months. Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles
Drug: EU Avastin® · Drug: Paclitaxel · Drug: carboplatin
BAT1706 15 mg/kg IV infusions ,every 3 weeks of a cycle for up to 6 cycles, followed for those with non-progressive disease with maintenance monotherapy with BAT1706 up to a maximum of 8 months. Drug: Paclitaxel 200mg/m² via IV infusions, every 3 weeks of a cycle for up to 6 cycles Drug: Carboplatin AUC 6.0 mg/mL•minute via IV infusions,every 3 weeks of a cycle for up to 6 cycles
Drug: BAT1706 · Drug: Paclitaxel · Drug: carboplatin
100 mg/4 mL
100 mg/4 mL
200 mg/m²
target area under the curve \[AUC\] 6 mg/mL•minute
Overall Response Rate
The primary efficacy endpoint is ORR at Week 18 (ORR18) based on tumor response evaluated according to RECIST 1.1 as assessed by CIR. Each patient will be assigned to one of the following RECIST 1.1 categories based on independent CIR, irrespective of protocol deviations or missing data: CR: complete response. PR: partial response. SD: stable disease. PD: progressive disease. NE: not evaluable (insufficient data)
Time frame: Week 18
Progression Free Survival Rate
Progression free survival rate at 12 months, defined as the proportion of patients being alive without documented progression 12 months after randomization, using Kaplan-Meier method.
Time frame: 8 months,1 year and 2 years
Progression Free Survival Time
Progression free survival time defined as the time from the date of randomization to the date of documented clinical or radiological progression or death due to any cause using Kaplan-Meier method.
Time frame: 8 months,1 year and 2 years
Overall Survival Rate
Overall survival rate at 12 months, defined as the proportion of patients being alive 12 months after randomization using Kaplan-Meier method.
Time frame: 8 months,1 year and 2 years
Overall Survival Time
Overall survival time defined as the time from randomization to death of any cause using Kaplan-Meier method.
Time frame: 8 months,1 year and 2 years
Overall Response Rate
ORR at Week 6 (ORR6) and ORR at Week 12 (ORR12), based on tumor response as assessed by CIR, and best ORR of confirmed responses at end of study assessed by local radiologist/Investigator if after Week 18 according to RECIST 1.1.
Time frame: Week 6 and Week 12
Duration of Response
Duration of response defined as the time from first documentation of a response (CR or PR) and the first documentation of progression (assessed by local radiologist/Investigator if after Week 18) according to RECIST 1.1.
Time frame: 8 months
Plasma Level of Anti Drug Antibodies (ADA) and Neutralizing Anti-drug Antibodies (NADA) Correlated With Bevacizumab Plasma Level
Plasma level of anti drug antibodies (ADA) and neutralizing anti-drug antibodies (NADA) correlated with bevacizumab plasma level
Time frame: 12 months
Bevacizumab Plasma Exposure Following Treatments of BAT1706 or EU Avastin®
Bevacizumab plasma exposure following treatments of BAT1706 or EU Avastin®
Time frame: 12 months
| Milestone | EU Avastin® | BAT1706 |
|---|---|---|
| Started | 326 | 325 |
| Completed | 209 | 222 |
| Not completed | 117 | 103 |
The primary efficacy endpoint is ORR at Week 18 (ORR18) based on tumor response evaluated according to RECIST 1.1 as assessed by CIR. Each patient will be assigned to one of the following RECIST 1.1 categories based on independent CIR, irrespective of protocol deviations or missing data: CR: complete response. PR: partial response. SD: stable disease. PD: progressive disease. NE: not evaluable (insufficient data)
| Participants | EU Avastin® | BAT1706 |
|---|---|---|
| Overall Response Rate | 156 | 145 |
Progression free survival rate at 12 months, defined as the proportion of patients being alive without documented progression 12 months after randomization, using Kaplan-Meier method.
Results for this outcome have not been posted.
Progression free survival time defined as the time from the date of randomization to the date of documented clinical or radiological progression or death due to any cause using Kaplan-Meier method.
Results for this outcome have not been posted.
Overall survival rate at 12 months, defined as the proportion of patients being alive 12 months after randomization using Kaplan-Meier method.
Results for this outcome have not been posted.
Overall survival time defined as the time from randomization to death of any cause using Kaplan-Meier method.
Results for this outcome have not been posted.
ORR at Week 6 (ORR6) and ORR at Week 12 (ORR12), based on tumor response as assessed by CIR, and best ORR of confirmed responses at end of study assessed by local radiologist/Investigator if after Week 18 according to RECIST 1.1.
Results for this outcome have not been posted.
Duration of response defined as the time from first documentation of a response (CR or PR) and the first documentation of progression (assessed by local radiologist/Investigator if after Week 18) according to RECIST 1.1.
Results for this outcome have not been posted.
Plasma level of anti drug antibodies (ADA) and neutralizing anti-drug antibodies (NADA) correlated with bevacizumab plasma level
Results for this outcome have not been posted.
Bevacizumab plasma exposure following treatments of BAT1706 or EU Avastin®
Results for this outcome have not been posted.
Collected over From the start of the first study medication administration until 28 days after discontinuation/completion of the study medication or up to Week 53 after randomization- All AEs, regardless of relationship to the study medication/study procedures. During the LTE study, only adverse events of special interest (AESIs) and SAEs until 28 days after the subject's last dose will be collected.. Non-serious events are listed at a 0.3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EU Avastin® | 4/324 (1.2%) | 119/324 (36.7%) | 8/324 (2.5%) |
| BAT1706 | 7/325 (2.2%) | 119/325 (36.6%) | 9/325 (2.8%) |
| Event | EU Avastin® | BAT1706 |
|---|---|---|
| Blood and lymphatic system disordersBlood and lymphatic system disorders | 46/324 | 31/325 |
| Infections and infestationsInfections and infestations | 22/324 | 27/325 |
| Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders | 19/324 | 21/325 |
| Gastrointestinal disordersGeneral disorders | 12/324 | 12/325 |
| Cardiac disordersCardiac disorders | 4/324 | 11/325 |
| Vascular disordersVascular disorders | 8/324 | 5/325 |
| General disorders and administration site conditionsGastrointestinal disorders | 4/324 | 8/325 |
| Nervous system disordersNervous system disorders | 4/324 | 4/325 |
| Event | EU Avastin® | BAT1706 |
|---|---|---|
| Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders | 3/324 | 5/325 |
| Renal and urinary disordersRenal and urinary disorders | 2/324 | 3/325 |
| Neoplasms benign, malignant and unspecified (inclcysts and polyps)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/324 | 0/325 |
| HepatobiliarydisordersHepatobiliary disorders | 1/324 | 1/325 |
| Age, Categorical(Participants) | EU Avastin® | BAT1706 | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 208 | 233 | 441 |
| >=65 years | 118 | 92 | 210 |
| Age, Continuous(years) | EU Avastin® | BAT1706 | Total |
|---|---|---|---|
| Median | 60 (26 to 88) | 61 (27 to 84) | 61 (26 to 88) |
| Sex: Female, Male(Participants) | EU Avastin® | BAT1706 | Total |
|---|---|---|---|
| Female | 97 | 97 | 194 |
| Male | 229 | 228 | 457 |
| Race (NIH/OMB)(Participants) | EU Avastin® | BAT1706 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 13 | 11 | 24 |
| Asian | 140 | 141 | 281 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 1 | 1 | 2 |
| White | 171 | 172 | 343 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | EU Avastin® | BAT1706 | Total |
|---|---|---|---|
| Turkey | 67 | 64 | 131 |
| China | 139 | 140 | 279 |
| Ukraine | 98 | 102 | 200 |
| South Africa | 6 | 2 | 8 |
| Mexico | 16 | 17 | 33 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2017 to primary completion in Nov 2019, 24 months.
Results were first posted in Sep 2021, 1 year 10 months after primary completion.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 24 months is below that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BAT1706
Carcinoma, Non-Small-Cell Lung →